Medicine

NTJM

Received: August 23, 1999 Accepted: Septembar 13, 1999

Yi-Chiang Hsu^a Chung-Hong Hu^b Woan-Ruoh Bee^{a,b} aInstitute of Medical Sciences, Taipei Medical College, bDepartment of Dermatology, Taipei Medical College Hospital, 250 Wu Hsing Street, Taipei 110-31, Taiwan, R.O.C.

Production and Secretion of Interleukin-12 (IL-12) in Patients with Atopic Dermatitis

Key Words

Interleukin-12 Atopic dermatitis Phosphodiesterase

ABSTRACT

ABS = Th1/Th2 cytokine imbalance has been demonstrated in patients with atopic dermatitis, and phosphodiesterase inhibitors have demonstrated efficacy in treating these patients; however, the pathogenesis of atopic dermatitis is still not clear. This study was performed to detect cytokine expression (IL-4, IL-6, IFN-y, IL-12, and IL-13) in patients with moderate to severe atopic dermatitis, and the effect of a non-selective phosphodiesterase inhibitor (3-isobutyl-1-methyl-xathine, IBMX) on these cytokines. Seven moderate to severe atopic dermatitis patients without previous medical treatments and 5 normal non-atopic subjects were recruited in this study. Cytokine expression was determined by ELISA from serum samples and by RT-PCR from peripheral blood mononuclear cells (PBMC). The effect of a non-selective phosphodiesterase inhibitor on cytokine expression was determined after a 48-h incubation of PBMCs with IBMX. Among the cytokines analyzed (IL-4, IL-6, IFN-7, IL-12, and IL-13), only the IL-12 level was significantly increased in atopic dermatitis patients (median = 55.66 ± 17.51 vs. 146.11 ±49.31; p < 0.05; student t-test), and its level was significantly reduced by IBMX treatment (median = 351.36 ± 26.34 vs. 42.58 ± 24.82 ; p < 0.01; student t-test). The facts that the steady-state IL-12 level is increased in atopic dermatitis and IBMX-treatment abrogates the increased level of IL-12 suggest that IL-12 may be involved in the pathogenesis of atopic dermatitis. This finding may also provide a potential pharmacological application of phosphodiesterase inhibitor in clinical management of atopic dermatitis.

INTRODUCTION

IL-12 is a recently described cytokine, ^{1,2} which plays a critical role in the development of Th1-like T

NTJM

Tel: 886-2-27361661 ext. 749 Fax: 886-2-23772150

cells.³⁻⁵ IL-12, originally called NK cell-stimulatory factor^{6,7} or cytotoxic lymphocyte maturation factor,⁸ is a heterodimeric molecule consisting of disulphidelinked 35-kD and 40-kD polypeptides.^{2,3} It is secreted

Dr. Woan-Ruoh Lee

Institute of Medical Sciences, Taipei Medical College and Department of Dermatology, Taipei Medical College Hospital 250 Wu Hsing Street, Taipei 110-31, Taiwan, R.O.C. Tel: 886-2-27372181 ext. 1122, Fax: 886-2-23778620

E-mail: cmbwrlee@mail.tmc.edu.tw